Literature DB >> 28397700

Narcotic bowel syndrome.

Adam D Farmer1, Jayne Gallagher2, Caroline Bruckner-Holt3, Qasim Aziz4.   

Abstract

Narcotic bowel syndrome is characterised by worsening abdominal pain in the context of escalating or continuous opioid therapy. Although narcotic bowel syndrome is rarely diagnosed, given the current epidemic of opioid use, it is likely to be under-recognised. The underlying pathophysiological mechanisms of narcotic bowel syndrome are incompletely understood; however, opioid-induced hyperalgesia is likely to be a central facet. The putative mechanisms of hyperalgesia include activation of bimodal opioid regulatory systems, counter-regulatory mechanisms, neuroinflammation, opioid facilitation, and interactions of the N-methyl D-aspartate receptor with opioids at the level of the spinal cord. The cornerstone of management is the development of a therapeutic alliance with the patient, education of the patient as to the mechanisms by which opioids might paradoxically worsen pain, and implementation of an opioid detoxification programme. Opioid detoxification regimens vary between centres, but frequently include tapering or substitution of opioids and concomitant co-administration of antidepressants, anxiolytics, and psychological therapies. Despite these interventions, recidivism rates remain high. Further prospective research is warranted to determine the epidemiology of narcotic bowel syndrome and delineate the most efficacious detoxification programmes.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28397700     DOI: 10.1016/S2468-1253(16)30217-5

Source DB:  PubMed          Journal:  Lancet Gastroenterol Hepatol


  8 in total

1.  Analgesic reduction during an interdisciplinary pain management programme: treatment effects and processes of change.

Authors:  Beth J Guildford; Aisling Daly-Eichenhardt; Bethany Hill; Karen Sanderson; Lance M McCracken
Journal:  Br J Pain       Date:  2017-10-02

Review 2.  Medical Management of Pain in Chronic Pancreatitis.

Authors:  Vikesh K Singh; Asbjørn M Drewes
Journal:  Dig Dis Sci       Date:  2017-05-18       Impact factor: 3.199

3.  Intravenous haloperidol for the treatment of intractable vomiting, cyclical vomiting, and gastroparesis.

Authors:  Brad E Schwartz; Karen Keller Baker; Andrew J Bleinberger; Amina Lleshi; Raul Cruz-Cano
Journal:  World J Emerg Med       Date:  2021

4.  Opioid-Induced Pronociceptive Signaling in the Gastrointestinal Tract Is Mediated by Delta-Opioid Receptor Signaling.

Authors:  Josue Jaramillo-Polanco; Cintya Lopez-Lopez; Yang Yu; Emma Neary; Alan Hegron; Meritxell Canals; Nigel W Bunnett; David E Reed; Alan E Lomax; Stephen J Vanner
Journal:  J Neurosci       Date:  2022-03-07       Impact factor: 6.709

Review 5.  Psychological comorbidity in gastrointestinal diseases: Update on the brain-gut-microbiome axis.

Authors:  Hannibal Person; Laurie Keefer
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2020-12-14       Impact factor: 5.067

6.  A Case of Wilkie's Syndrome: Consideration of Alternative Diagnosis in the Setting of Chronic Abdominal Pain.

Authors:  John D Adame; Giselle Falconi; Seneca Harberger
Journal:  Cureus       Date:  2019-11-05

Review 7.  Less Well-Known Consequences of the Long-Term Use of Opioid Analgesics: A Comprehensive Literature Review.

Authors:  Aleksandra Kotlińska-Lemieszek; Zbigniew Żylicz
Journal:  Drug Des Devel Ther       Date:  2022-01-18       Impact factor: 4.162

Review 8.  Management of Opioid-Induced Constipation and Bowel Dysfunction: Expert Opinion of an Italian Multidisciplinary Panel.

Authors:  Roberto De Giorgio; Furio Massimino Zucco; Giuseppe Chiarioni; Sebastiano Mercadante; Enrico Stefano Corazziari; Augusto Caraceni; Patrizio Odetti; Raffaele Giusti; Franco Marinangeli; Carmine Pinto
Journal:  Adv Ther       Date:  2021-06-04       Impact factor: 3.845

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.